Takeda Pharmaceutical (NYSE:TAK – Get Rating) updated its FY 2022 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $3.99-$3.99 for the period. The company issued revenue guidance of $30.39 billion-$30.39 billion.
NYSE TAK opened at $14.41 on Wednesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.81 and a current ratio of 1.21. The stock has a 50-day simple moving average of $14.62 and a 200 day simple moving average of $14.43. The stock has a market capitalization of $45.60 billion, a PE ratio of 16.95 and a beta of 0.73. Takeda Pharmaceutical has a twelve month low of $13.17 and a twelve month high of $17.43.
Large investors have recently bought and sold shares of the company. Brown Brothers Harriman & Co. acquired a new position in shares of Takeda Pharmaceutical during the first quarter valued at about $105,000. Sequoia Financial Advisors LLC acquired a new position in Takeda Pharmaceutical in the 1st quarter valued at approximately $156,000. Evergreen Capital Management LLC bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $159,000. Beacon Pointe Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 11.2% during the 1st quarter. Beacon Pointe Advisors LLC now owns 11,861 shares of the company’s stock worth $170,000 after purchasing an additional 1,190 shares in the last quarter. Finally, EP Wealth Advisors LLC bought a new stake in shares of Takeda Pharmaceutical during the first quarter valued at approximately $196,000. Institutional investors own 2.40% of the company’s stock.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines.
- Get a free copy of the StockNews.com research report on Takeda Pharmaceutical (TAK)
- American Well Corporation Stock May Well Be Bottoming
- There Are Cracks In The Paint At Sherwin-Williams
- 3 Outperforming Energy Stocks with More in the Tank
- Three Beaten Down Stocks The Insiders Are Buying
- Should Medtronic Make the Cut For Your Recovery Watchlist?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.